ProCE Banner Activity

My Take on Pembrolizumab Plus Chemotherapy for PD-L1–Positive Advanced TNBC

Clinical Thought
With pembrolizumab plus chemotherapy now approved for PD-L1–positive advanced TNBC, how can we leverage this regimen for treating patients with this challenging disease? Here’s my take.

Released: November 20, 2020

Expiration: November 19, 2021

No longer available for credit.

Share

Faculty

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH, has disclosed that she has received funds for research support from Bristol-Myers Squibb and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Genomic Health, Merck, Pfizer, and Puma.